This article is more than 5 years old. Information may no longer be current.

FDA approves label update for Xiaflex

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Endo Pharmaceuticals recently announced the FDA has approved a label update for Xiaflex to include the treatment of Dupuytren’s contracture.

Patients indicated for treatment with Xiaflex are those with Dupuytren’s who have a palpable cord. The update comes on the heels of a long-term observational study demonstrating diminished recurrence of Dupuytren’s for up to 5 years when treated with Xiaflex, according to a company press release.

“The FDA’s initial approval of Xiaflex more than 5 years ago brought an effective, non-surgical and minimally invasive option for the treatment of adult [Dupuytren’s] patients,” Sue Hall, PhD, Endo’s executive vice president, chief scientific officer, and global head of research and development and quality, said in the release. “The updated label that includes data in patients with recurring contractures coupled with the 5-year follow-up data in previously-treated patients further supports the efficacy and safety of Xiaflex for initial and retreatment of [Dupuytren’s] patients.”

Reference: www.endo.com.